GlassScriptPhysician profile
Steven H Pack
NPI 1346351194
$6,681.44
in general payments reported to CMS, 2019-2025
38 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $1,471 · 2023: $1,085 · 2024: $1,661 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,494.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,550.96 | 2021-2025 | |
| Novo Nordisk INC | $990.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $557.77 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $493.73 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.17 | 2021-2025 | Xifaxan, Trulance |
| Antares Pharma, INC. | $239.93 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $226.67 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $219.15 | 2024-2025 | Korlym |
| Shield Therapeutics INC | $212.36 | 2022-2025 | Accrufer |
| Janssen Pharmaceuticals, INC | $207.35 | 2022-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $181.81 | 2021-2024 | Austedo Xr |
| Inspire Medical Systems, INC. | $174.37 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $169.85 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $134.63 | 2021-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $116.39 | 2021-2024 | Veozah |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $114.73 | 2021-2024 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $114.35 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $96.90 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.34 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $57.57 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Kowa Pharmaceuticals America, INC. | $56.52 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $47.56 | 2024-2025 | Gemtesa |
| Nevro Corp. | $46.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.88 | 2024-2025 | Jardiance |
| Hologic Sales and Service, LLC | $43.11 | 2022-2024 | Aptima |
| Alexion Pharmaceuticals, INC. | $29.81 | 2021-2023 | Strensiq |
| Tolmar, INC. | $29.76 | 2024-2025 | Jatenzo |
| E.R. Squibb & Sons, L.L.C. | $24.40 | 2025 | Cobenfy |
| Kyowa Kirin, INC. | $24.38 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $20.38 | 2021 | |
| Insulet Corporation | $18.49 | 2022 | |
| Halozyme INC | $18.07 | 2023 | |
| Allergan, INC. | $16.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2021 | |
| Amgen INC. | $15.58 | 2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $14.90 | 2021 | |
| Horizon Therapeutics Plc | $14.88 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $14.35 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.